Immunome (IMNM) news
Recent news
Immunome Q2 EPS USD -0.65
AInvest Wire · Aug 11, 2026Immunome reports inducement grants under Nasdaq listing rule 5635(c)(4)
Immunome, Inc. (Nasdaq: IMNM) has made several inducement grants to new employees under its 2024 Inducement Plan, in compliance with Nasdaq Listing Rule 5635(c)(4). On June 1, 2026, the Compensation Committee of the Board of Directors granted non-statutory stock options to purchase 353,000 shares…
AInvest Wire · Jul 7, 2026Immunome - plans IND submission for IM-1340 in mid-2026 and IM-1335 in late 2026
Immunome, Inc. (Nasdaq: IMNM) has outlined plans to submit Investigational New Drug (IND) applications for two of its preclinical antibody-drug conjugate (ADC) programs, IM-1340 and IM-1335 , in mid- and late 2026, respectively. Both programs are directed at undisclosed solid tumor targets and…
AInvest Wire · Jun 11, 2026ImportantImmunome gains 28% pre-market as varegacestat trial meets primary endpoint
AInvest Wire · Dec 15, 2025ImportantImmunome Shares Hit 52-Week High After Tuesday Deal With Ayala Pharma
Immunome Shares Hit 52-Week High After Tuesday Deal With Ayala Pharma Immunome, a clinical-stage biopharmaceutical company, recently announced a deal with Ayala Pharmaceuticals to acquire AL102 and related drug candidate AL101. This news caused Immunome shares to hit a 52-week high, rising 16% to…
AInvest Wire · Feb 7, 2024Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.